Biomark Diagnostics Inc
20B
Company Profile
Business description
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company’s objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
Contact
130 - 3851 Shell Road
RichmondBCV6X 2W2
CANT: +1 604 836-6950
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 March 2026
Employees
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
We view the shares are materially overvalued.
stocks
Chart of the Week: Lithium is rebounding on rising demand
The mining sector is significantly overvalued on average but select value to be found.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,320.30 | 20.10 | -0.22% |
| CAC 40 | 8,429.03 | 0.00 | 0.00% |
| DAX 40 | 25,278.21 | 279.81 | 1.12% |
| Dow JONES (US) | 49,662.66 | 129.47 | 0.26% |
| FTSE 100 | 10,686.18 | 130.01 | 1.23% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,753.63 | 175.25 | 0.78% |
| Nikkei 225 | 57,684.22 | 540.38 | 0.95% |
| NZX 50 Index | 13,444.20 | 197.18 | 1.49% |
| S&P 500 | 6,881.31 | 38.09 | 0.56% |
| S&P/ASX 200 | 9,090.80 | 19.70 | -0.22% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |